What Is Lowest Net Cost Prescription Routing?

The net cost of a prescription is the final amount the plan pays after all pricing adjustments have been applied. This includes the drug acquisition cost, dispensing fees, administrative fees, rebates, discounts, and any other financial adjustments.

Net cost is not the same as list price. A drug with a $1,000 list price and a $600 rebate has a net cost of $400 to the plan. A different drug with a $450 list price and no rebate has a net cost of $450. In this case, the more expensive list-price drug is actually the lower net-cost option - but only if the rebate is fully passed through to the plan.

Net cost is also not the same as the price the member pays. The member's cost-share (copay or coinsurance) is separate from the plan's net cost. A plan can have a low net cost while the member pays a high copay, or vice versa.

For plan sponsors, net cost is the number that matters because it represents the actual financial impact on the plan. It is also the number that is hardest to verify because it depends on pricing components that are often opaque, delayed, or subject to retroactive adjustment.

PBM Specialty Pharmacy - The PBM's owned or affiliated specialty pharmacy, typically used for high-cost medications requiring special handling, clinical monitoring, or prior authorization.

PBM Mail-Order Pharmacy - The PBM's mail-order operation, usually offering 90-day fills at negotiated rates.

Retail Pharmacy - Chain and independent pharmacies where members fill prescriptions in person.

Manufacturer-Direct Programs - Copay programs, patient assistance programs, and direct pricing offered by drug manufacturers, including DTC, DTP, and DTE models.

Independent Community Pharmacy - Independently owned pharmacies that are not affiliated with PBMs, insurers, or group purchasing organizations.

The critical point: if any channel is excluded from the evaluation, the routing cannot be described as "lowest net cost." A system that evaluates only PBM specialty and PBM mail but ignores manufacturer-direct options is not performing a complete comparison. A system that excludes independent pharmacy is not evaluating all available retail options.

Real-time routing means the evaluation happens at the point of decision - when the prescription is received and before it is filled. The system evaluates all channels, compares net costs, and routes the prescription to the lowest-cost option. The decision is made before the member receives the medication.

Retrospective analysis means the evaluation happens after the fact - in a quarterly review, an annual audit, or a PBM performance report. The prescription has already been filled. The plan has already paid. The analysis can identify that a lower-cost option existed, but it cannot change the outcome.

Most PBM reporting is retrospective. Even PBMs that claim "lowest net cost" routing are typically comparing within their own channels (specialty vs. mail vs. retail) rather than evaluating external channels like manufacturer-direct programs or independent pharmacies.

Lowest compared to what? If the comparison only includes the PBM's own channels - its specialty pharmacy, its mail-order pharmacy, its contracted retail network - the evaluation is incomplete. Manufacturer-direct pricing and independent pharmacy options may offer lower costs but are not included in the comparison.

Lowest at what point in time? If the "lowest net cost" is calculated retrospectively after rebates and DIR fees are reconciled, the actual cost at the point of dispensing may have been higher. Retroactive adjustments can change the net cost months after the prescription was filled.

Lowest for whom? A PBM that owns pharmacies has a financial incentive to route prescriptions to its own channels, even when an independent pharmacy or manufacturer-direct option is cheaper for the plan. The PBM's "lowest net cost" may reflect the lowest cost within its vertically integrated operation, not the lowest cost available in the market.

Who verified it? If the entity reporting "lowest net cost" is the same entity that made the routing decision, the plan sponsor is relying on self-reported data. There is no independent verification.

Decision-level documentation is the evidence that lowest-net-cost routing actually occurred. For each prescription, the documentation should include:

• All channels that were evaluated
• The net cost calculated for each channel
• The program rules that were applied (formulary, prior authorization, quantity limits, cost-share design)
• Which channel was selected and why
• The member's cost-share amount and how it was calculated
• The financial reconciliation - what the plan paid, what the member paid, what was billed

This is not an aggregate report. It is a per-prescription record that can be audited individually. If a plan sponsor wants to verify that prescription #47,293 was routed to the lowest net cost, they can pull that specific record and see exactly what happened.

This level of documentation is standard in other financial systems. Securities trades have execution reports. Insurance claims have adjudication records. Pharmacy benefit decisions - which can involve thousands of dollars per prescription - have historically had nothing comparable.

Under ERISA, plan fiduciaries must act with prudence and in the best interest of plan participants. The Consolidated Appropriations Act of 2026 requires plan sponsors to attest that PBM fees and compensation are reasonable.

Decision-level documentation from lowest-net-cost routing provides the specific, per-script evidence that fiduciaries need. Rather than relying on aggregate PBM reports that summarize overall performance, plan sponsors can point to individual routing records that demonstrate each decision was evaluated across all channels and routed to the optimal option.